Annual General Meeting Statement
Proteome Sciences plc reported at its Annual General Meeting that its services business is experiencing good order levels and a recovery in TMT and reagent sales in the first half of the year, following budget cuts in 2025. The company believes its significant investment over the past two years positions it well to achieve substantial returns in the growing proteomics field.
Select text to share a quote on X · sign in to keep highlights & notes in your PRM notes
At the Company's Annual General Meeting ("AGM") being held today at 12.00 noon, the Chairman, Christopher Pearce, made the following statement:
"Good progress is being made in order levels in our services business and the recovery that we hoped for in TMT and reagent sales continues in the first half following the cuts in US NIH budgets and academic grants in 2025.
With the significant investment made in the business over the last 2 years, we believe we are well positioned to deliver substantial returns from our activities in the fast growing field of proteomics."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.